Cardiology Device Lobbyists Focused On Reimbursement, Coronavirus, Trade Issues In Early 2020
Industry lobbyists include former legislators, key committee staffers, say lobby reports
Cardiology device firms relied primarily on in-house lobbyists but also recruited external groups to sway lawmakers to adopt favorable positions on reimbursement, COVID-19, international trade and other issues from January-March 2020, says this Medtech Insight analysis.
You may also be interested in...
Advanced imaging companies spent hundreds of thousands of dollars in Q1 2020 lobbying Congress on issues as diverse as the national COVID-19 response and cybersecurity issues but are most interested in resolving device servicing and remanufacturing problems.
The COVID-19 pandemic is severely hindering patient access to transcatheter aortic valve replacement procedures. Edwards Lifesciences, the market leader, is hopeful that TAVR volumes will recover by the end of 2020, but that will be too late for many patients.
The US Department of Veterans Affairs is giving the VA’s four prime vendors for medical and surgical supplies more ability to directly choose suppliers as part of ongoing updates to the Medical/Surgical Prime Vendor (MSPV 2.0) program. Here’s what device manufacturers should know as the program rolls out.